PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652

Cell Rep. 2023 Nov 28;42(11):113343. doi: 10.1016/j.celrep.2023.113343. Epub 2023 Oct 31.

Abstract

The intrinsic regulation of programmed death ligand-1 (PD-L1) expression remains unclear. Here, we report that zinc-finger protein 652 (ZNF652) is a potent transcription repressor of PD-L1. ZNF652 frequently experiences loss of heterozygosity (LOH) in various cancers. Higher LOH rate and lack of estrogen-inducible transcription lead to suppressed expression of ZNF652 in triple-negative breast cancer (TNBC). Mechanistically, ZNF652 is physically associated with the NuRD transcription co-repressor complex to repress a cohort of genes, including PD-L1. Overexpression of ZNF652 inhibits PD-L1 transcription, whereas depletion of ZNF652 upregulates PD-L1. Loss of ZNF652 in TNBC unleashes PD-L1-mediated immune evasion both in vitro and in vivo. Significantly, ZNF652 expression is progressively lost during breast cancer progression, and a low ZNF652 level is correlated with elevated PD-L1 expression, less infiltrated CD8+ T cells, and poor prognosis in TNBC. Our study provides insights into PD-L1 regulation and supports the pursuit of ZNF652 as a potential biomarker and drug target for breast cancer immunotherapy.

Keywords: CP: Cancer; PD-L1; ZNF652; breast cancer; cancer immune evasion; transcription repression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / metabolism
  • CD8-Positive T-Lymphocytes / metabolism
  • Humans
  • Immune Evasion
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Triple Negative Breast Neoplasms* / metabolism

Substances

  • CD274 protein, human
  • B7-H1 Antigen
  • Transcription Factors